查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446930

中樞神經系統 (CNS) 治療市場：按疾病類型：2024-2033 年全球機會分析與產業預測

Central Nervous System (CNS) Therapeutics Market By Disease Type (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 246 Pages | 商品交期: 2-3個工作天內

價格

中樞神經系統（CNS）治療市場2023年估值為1141.4558億美元，預計到2033年將達到1990.983億美元，2024年至2033年複合年成長率為5.7%。中樞神經系統（CNS）是一個由神經和細胞組成的複雜網路，在協調和調節身體活動中發揮重要作用。中樞神經系統由腦和脊髓組成，是整個神經系統的主要控制中心。中樞神經系統藥物旨在緩解症狀、改善認知功能和減緩疾病進展。中樞神經系統治療主要涉及使用藥物來解決中樞神經系統內的疾病或失衡。它針對各種神經和神經退化性疾病阿茲海默症和帕金森氏症等神經退化性疾病到情緒障礙、焦慮症和精神病等精神疾病。

中樞神經系統（CNS）治療市場-IMG1

由於中樞神經系統（CNS）疾病盛行率的迅速增加以及支持研究和創新的研究津貼等政府主導，中樞神經系統（CNS）治療市場預計將顯著成長。中樞神經系統（CNS）疾病的日益普及已成為中樞神經系統（CNS）治療市場的主要促進因素。這是由於生活方式緊張、忽視心理健康以及人口老化加劇所造成的。特別是在高齡化社會，阿茲海默症、帕金森氏症等神經退化性疾病迅速增加。例如，根據美國疾病管制與預防中心的數據，大約有 670 萬 65 歲以上的美國患有阿茲海默症。

此外，現代快節奏的生活方式以高壓力水平和久坐習慣為特徵，與焦慮和憂鬱症等精神疾病的風險增加有關。例如，根據國家醫學圖書館的數據，預計到 2021 年，超過五分之一的美國成年人將患有精神疾病。製藥公司越來越注重發現和開發針對各種中樞神經系統疾病的新藥和治療方法。神經科學的突破以及對這些疾病潛在機制的更深入了解為更有效和更有針對性的治療方法鋪平了道路。隨著患者和醫療保健提供者尋求先進的干涉措施來解決中樞神經系統疾病的根本原因而不僅僅是緩解症狀，對中樞神經系統藥物的需求預計將飆升。因此，中樞神經系統（CNS）疾病盛行率的增加預計將顯著促進中樞神經系統（CNS）治療市場的成長。

此外，政府的有利津貼，舉措將推動市場成長。世界各國政府已經認知到需要解決神經退化性疾病、精神疾病和神經系統疾病等疾病，這些疾病給全球醫療保健系統帶來了沉重負擔。促進研究的一項值得注意的舉措是提供研究津貼，專門用於提高我們對中樞神經系統的了解並開發新的治療性介入。研究津貼作為科學研究的催化劑，促進研究人員、學術界和製藥公司之間的合作。例如，美國帕金森氏症協會向研究科學家提供高達 75,000 美元的研究津貼。美國氏症協會研究津貼旨在支持旨在獲得有關病理學新知識的研究。

津貼提案可以解決從基礎科學到復健計劃的任何研究問題。美國帕金森氏症協會旨在鼓勵新研究人員進入帕金森氏症研究領域，並支持該領域值得研究的重要新想法。政府機構透過提供津貼在促進創新治療方法和療法的開發方面發揮著至關重要的作用。因此，研究津貼等有利的政府舉措預計將推動市場成長。

然而，中樞神經系統（CNS）治療的高成本已成為限制市場成長的主要問題。神經系統疾病的複雜性通常需要複雜且專門的治療性介入，從而導致高昂的研發成本。此外，衛生當局施加的嚴格監管要求導致中樞神經系統疾病藥物上市需要漫長且資源密集的時間。這些高昂的成本轉嫁給了最終用戶，包括患者和醫療保健系統，限制了中樞神經系統治療的取得和負擔能力。因此，中樞神經系統（CNS）治療的高成本可能會抑制市場成長。

中樞神經系統（CNS）治療市場按疾病類型和地區細分。依疾病類型分為神經血管疾病、中樞神經系統創傷、精神健康、神經退化性疾病、感染疾病、癌症等。心理健康領域進一步分為心理健康焦慮症、癲癇、情緒障礙、精神障礙等。

神經退化性疾病進一步分為阿茲海默症、帕金森氏症、多發性硬化症、亨丁頓舞蹈症、肌萎縮性側索硬化症等。依地區分類，市場分為北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家）、亞太地區（中國、日本、澳洲、印度、韓國、其他地區） ） 、亞太地區（巴西、日本、阿拉伯、澳洲、印度、韓國和亞太地區其他地區）。

相關人員的主要利益

  • 該報告提供了 2023 年至 2033 年中樞神經系統 (CNS) 治療市場分析的細分市場、當前趨勢、估計/趨勢和動態的定量分析，並提供了領先的中樞神經系統 (CNS)動態市場的定量分析分析. 確定藥品市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商和買家網路的潛力。
  • 中樞神經系統（CNS）治療市場區隔的詳細分析有助於確定市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於對標，並可以清楚了解市場參與者的當前地位。
  • 它包括對區域和全球中樞神經系統 (CNS) 治療市場趨勢、主要企業、細分市場、應用領域、市場成長策略等的分析。

可使用此報告進行客製化（需要額外費用和時間表）

  • 根據客戶興趣加入公司簡介
  • 公司簡介的擴充列表
  • 歷史市場資料

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 神經系統疾病盛行率上升
      • 提高對中樞神經系統疾病的認知和診斷
      • 主要企業研發快速增加
    • 抑制因素
      • 中樞神經系統（CNS）藥物高成本
    • 機會
      • 藥物傳輸技術的進步

第4章中樞神經系統（CNS）治療市場：依疾病類型

  • 概述
  • 神經血管疾病
  • 中樞神經系統創傷
  • 精神健康
    • 按精神健康疾病類型分類的中樞神經系統 (CNS) 治療藥物市場
  • 神經退化性疾病
    • 神經神經退化性疾病的中樞神經系統 (CNS) 治療市場：依疾病類型
  • 感染疾病
  • 中樞神經系統癌症
  • 其他

第5章中樞神經系統（CNS）治療市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第6章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2023年主要企業定位

第7章 公司簡介

  • Johnson and Johnson
  • Eli Lilly and Company.
  • Merck & Co Inc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche AG
  • Takeda Pharmaceutical Company Ltd.
  • Viatris Inc.
  • UCB Pharma
  • Biogen
Product Code: A305147

The Central Nervous System (CNS) Therapeutics Market was valued for $114,145.58 million in 2023 and is estimated to reach $199,098.30 million by 2033, exhibiting a CAGR of 5.7% from 2024 to 2033. The central nervous system (CNS) is a complex network of nerves and cells that play a crucial role in coordinating and regulating the body's activities. It comprises the brain and spinal cord, serving as the primary control center for the entire nervous system. Central nervous system therapeutics aim to alleviate symptoms, improve cognitive function, and slow down disease progression. Central nervous system therapeutics primarily involve the use of drugs to address disorders and imbalances within the central nervous system. The medications target various neurological and psychiatric conditions, ranging from neurodegenerative diseases like Alzheimer's and Parkinson's to mental health disorders such as mood disorders, anxiety, and psychotic disorders.

Central Nervous System (CNS) Therapeutics Market - IMG1

The central nervous system (CNS) therapeutics market is expected to register significant growth, owing to surge in prevalence of CNS disorders, and favorable government initiative such as research grants to support research and innovation. The rise in prevalence of CNS disorders has emerged as a major driver for the central nervous system (CNS) therapeutics market. This can be attributed to the stressful lifestyle, negligence towards mental health, and rise in geriatric population. The aging population, in particular, has witnessed a surge in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. For instance, according to Center for Disease Control and Prevention, it was estimated that around 6.7 million Americans aged 65 years or older had Alzheimer's disease.

Additionally, the modern, fast-paced lifestyle, marked by high stress levels and sedentary habits, has been associated with a heightened risk of mental health disorders like anxiety and depression. For instance, according to National Library of Medicine, in 2021, it was estimated that that more than one in five U.S. adults live with a mental illness. Pharmaceutical companies are increasingly focusing on the discovery and development of novel drugs and therapies targeting various CNS conditions. Breakthroughs in neuroscience and a deeper understanding of the underlying mechanisms of these disorders have paved the way for more effective and targeted treatment options. The demand for CNS therapeutics is expected to surge as patients and healthcare providers seek advanced interventions that not only alleviate symptoms but also address the root causes of the CNS disorders. Thus, the rise in prevalence of CNS disorders is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market.

In addition, favorable government initiatives such as research grants to support research and innovation in treating central nervous system disorders are expected to drive the growth of the market. Governments around the world are recognizing the critical need to address conditions such as neurodegenerative diseases, psychiatric disorders, and neurological disorders, which collectively pose a substantial burden on global healthcare systems. One notable initiative driving the research is the provision of research grants specifically dedicated to advancing our understanding of the central nervous system and developing novel therapeutic interventions. The research grants serve as a catalyst for scientific exploration, fostering collaboration between researchers, academia, and pharmaceutical companies. For instance, American Parkinson Disease Association, awards research grant of maximum of $75,000 to research scientists. American Parkinson Disease Association Research Grants are intended to support research aimed at developing new insights into the pathophysiology, etiology and treatment of Parkinson's disease.

Grant proposals can address research questions anywhere along the pipeline from basic science to rehabilitation-focused projects. American Parkinson Disease Association seeks to promote the entry of new investigators into the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation. By providing grants governments agencies are playing a pivotal role in accelerating the development of innovative treatments and therapies. Thus, favorable government initiatives such as research grants are expected to drive the growth of the market.

However, the high cost of the central nervous system (CNS) therapeutic drug has emerged as major concerns restraining the growth of the market. The complex nature of neurological disorders often necessitates sophisticated and specialized therapeutic interventions, leading to elevated research and development expenses. Additionally, the stringent regulatory requirements imposed by health authorities contribute to the lengthy and resource-intensive process of bringing CNS drugs to market. These substantial costs are then transferred to end-users, comprising patients and healthcare systems, thereby limiting accessibility and affordability of the CNS drugs. Thus, the high cost of the central nervous system (CNS) therapeutic drug might restrain the growth of the market.

The central nervous system (CNS) therapeutics market is segmented based on disease type and region. By disease type, it is divided into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, cancer, and others. The mental health segment is further segmented into mental health anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others.

In addition, the neurodegenerative diseases are further classified into Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's Disease, amyotrophic lateral sclerosis, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Biogen Inc, Johnson and Johnson, Eli Lilly and Company Inc, Merck and Co. Inc, F. Hoffmann-La Roche AG, Novartis AG, Takeda Pharmaceuticals, Viatris, UCB, and Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the central nervous system (cns) therapeutics market analysis from 2023 to 2033 to identify the prevailing central nervous system (cns) therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the central nervous system (cns) therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global central nervous system (cns) therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Disease Type

  • Neurodegenerative Diseases
    • Disease Type
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Huntington's Disease
    • Amyotrophic Lateral Sclerosis
    • Others
  • Infectious Diseases
  • CNS Cancer
  • Others
  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
    • Disease Type
    • Anxiety Disorders
    • Epilepsy
    • Mood Disorders
    • Psychotic Disorders
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Johnson and Johnson
    • Eli Lilly and Company.
    • Merck & Co Inc
    • Novartis AG
    • Biogen
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Takeda Pharmaceutical Company Ltd.
    • Viatris Inc.
    • UCB Pharma

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. High intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of the neurological conditions
      • 3.4.1.2. Rise in awareness and diagnosis of CNS disorders
      • 3.4.1.3. Surge in research and development by key players
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of central nervous system (CNS) therapeutics
    • 3.4.3. Opportunities
      • 3.4.3.1. Technological advancements in drug delivery

CHAPTER 4: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Neurovascular Diseases
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. CNS Trauma
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Mental Health
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
    • 4.4.4. Mental Health Central Nervous System (CNS) Therapeutics Market by Disease Type
  • 4.5. Neurodegenerative Diseases
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
    • 4.5.4. Neurodegenerative Diseases Central Nervous System (CNS) Therapeutics Market by Disease Type
  • 4.6. Infectious Diseases
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. CNS Cancer
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Disease Type
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Disease Type
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Disease Type
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Disease Type
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Disease Type
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Disease Type
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Disease Type
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Disease Type
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Disease Type
      • 5.3.3.5. Spain
      • 5.3.3.5.1. Market size and forecast, by Disease Type
      • 5.3.3.6. Rest of Europe
      • 5.3.3.6.1. Market size and forecast, by Disease Type
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Disease Type
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Disease Type
      • 5.4.3.2. China
      • 5.4.3.2.1. Market size and forecast, by Disease Type
      • 5.4.3.3. India
      • 5.4.3.3.1. Market size and forecast, by Disease Type
      • 5.4.3.4. Australia
      • 5.4.3.4.1. Market size and forecast, by Disease Type
      • 5.4.3.5. South Korea
      • 5.4.3.5.1. Market size and forecast, by Disease Type
      • 5.4.3.6. Rest of Asia-Pacific
      • 5.4.3.6.1. Market size and forecast, by Disease Type
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Disease Type
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Brazil
      • 5.5.3.1.1. Market size and forecast, by Disease Type
      • 5.5.3.2. Saudi Arabia
      • 5.5.3.2.1. Market size and forecast, by Disease Type
      • 5.5.3.3. South Africa
      • 5.5.3.3.1. Market size and forecast, by Disease Type
      • 5.5.3.4. Rest of LAMEA
      • 5.5.3.4.1. Market size and forecast, by Disease Type

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

  • 7.1. Johnson and Johnson
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
  • 7.2. Eli Lilly and Company.
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Merck & Co Inc
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
  • 7.4. Novartis AG
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
    • 7.4.6. Business performance
    • 7.4.7. Key strategic moves and developments
  • 7.5. Teva Pharmaceutical Industries Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
    • 7.5.7. Key strategic moves and developments
  • 7.6. F. Hoffmann-La Roche AG
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
  • 7.7. Takeda Pharmaceutical Company Ltd.
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
    • 7.7.6. Business performance
  • 7.8. Viatris Inc.
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. UCB Pharma
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
    • 7.9.6. Business performance
  • 7.10. Biogen
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio
    • 7.10.6. Business performance
    • 7.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 02. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. GLOBAL MENTAL HEALTH CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 06. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 07. GLOBAL NEURODEGENERATIVE DISEASES CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 08. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 09. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY REGION, 2023-2033 ($MILLION)
  • TABLE 10. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 14. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 15. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 16. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 17. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 18. EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 19. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 20. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 21. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 22. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 23. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 24. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 25. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 26. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 27. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 28. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 29. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 30. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 31. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 32. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 33. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 34. LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2033 ($MILLION)
  • TABLE 39. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 40. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 41. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
  • TABLE 42. JOHNSON AND JOHNSON: SERVICE SEGMENTS
  • TABLE 43. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 44. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 45. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 46. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
  • TABLE 47. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 48. ELI LILLY AND COMPANY.: KEY STRATERGIES
  • TABLE 49. MERCK & CO INC: KEY EXECUTIVES
  • TABLE 50. MERCK & CO INC: COMPANY SNAPSHOT
  • TABLE 51. MERCK & CO INC: PRODUCT SEGMENTS
  • TABLE 52. MERCK & CO INC: PRODUCT PORTFOLIO
  • TABLE 53. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 54. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 55. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 56. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 57. NOVARTIS AG: KEY STRATERGIES
  • TABLE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 63. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 64. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 65. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 66. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 67. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
  • TABLE 68. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
  • TABLE 69. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
  • TABLE 70. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
  • TABLE 71. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 72. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 73. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 74. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 75. UCB PHARMA: KEY EXECUTIVES
  • TABLE 76. UCB PHARMA: COMPANY SNAPSHOT
  • TABLE 77. UCB PHARMA: PRODUCT SEGMENTS
  • TABLE 78. UCB PHARMA: PRODUCT PORTFOLIO
  • TABLE 79. BIOGEN: KEY EXECUTIVES
  • TABLE 80. BIOGEN: COMPANY SNAPSHOT
  • TABLE 81. BIOGEN: PRODUCT SEGMENTS
  • TABLE 82. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 83. BIOGEN: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2023 TO 2033)
  • FIGURE 04. TOP INVESTMENT POCKETS IN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, BY DISEASE TYPE, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEUROVASCULAR DISEASES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS TRAUMA, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR MENTAL HEALTH, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR CNS CANCER, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 19. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 20. U.S. CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 21. CANADA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 22. MEXICO CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 23. GERMANY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 24. FRANCE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 25. UK CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 26. ITALY CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 27. SPAIN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 28. REST OF EUROPE CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 29. JAPAN CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. CHINA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. INDIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. AUSTRALIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. SOUTH KOREA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. BRAZIL CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 36. SAUDI ARABIA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 37. SOUTH AFRICA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 38. REST OF LAMEA CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET, 2023-2033 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2024)
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2024)
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2024)
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: CENTRAL NERVOUS SYSTEM (CNS) THERAPEUTICS MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2023
  • FIGURE 46. JOHNSON AND JOHNSON: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. MERCK & CO INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. MERCK & CO INC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. MERCK & CO INC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. UCB PHARMA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. UCB PHARMA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)